Brazil approval adds a meaningful new market for acoramidis, reinforcing the drug's global commercial trajectory. Monitor H2 2026 launch execution and any upcoming regulatory decisions in additional countries. The strong Phase 3 data and multiple prior approvals de-risk this expansion — no new clinical data was required.
Price Chart
Executive Summary
BridgeBio Pharma announced that Brazilian health regulator ANVISA approved acoramidis (BEYONTTRA) for ATTR-CM, adding a sixth major market to its approvals. The drug demonstrated a 42% reduction in composite all-cause mortality and recurrent cardiovascular hospitalization events versus placebo at Month 30 in the Phase 3 ATTRibute-CM study. Commercialization in Brazil, via partner Biopas, is expected to begin in H2 2026, expanding the drug's global reach beyond the U.S., EU, UK, Switzerland, and Japan.
Key Facts
- ANVISA (Brazil) approved acoramidis (BEYONTTRA) for ATTR-CM in adults.
- Approval based on Phase 3 ATTRibute-CM study showing 42% reduction in composite ACM and recurrent CVH events at Month 30 vs placebo.
- 50% reduction in cumulative frequency of CVH events at Month 30 vs placebo.
- Acoramidis is the first and only approved ATTR-CM treatment in Brazil with a label specifying near-complete (≥90%) TTR stabilization.
- Commercialization in Brazil via Biopas (Swixx BioPharma) expected to begin in H2 2026.
- Acoramidis previously approved in U.S. (Nov 2024), EU (Feb 2025), Japan (Mar 2025), UK (Apr 2025), and Switzerland.
- BridgeBio market cap ~$13.5B; analyst consensus 97% bullish (29 of 30 analysts Buy/Strong Buy).
Financial Impact
Expands total addressable market for acoramidis to Brazil, the largest Latin American pharmaceutical market. No specific revenue guidance provided; prior U.S. approval in Nov 2024 and EU/Japan approvals in early 2025 already established commercial base.
Risk Factors
- Commercialization in Brazil depends on partner Biopas execution; any delays in H2 2026 launch could disappoint.
- Pricing and reimbursement negotiations in Brazil may limit initial uptake.
- Competition from Pfizer's tafamidis (Vyndamax) and other emerging ATTR-CM therapies in the Brazilian market.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3288693 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 8-K | $76.59 $65.97 | ▼ −13.87% | ▼ −13.68% | $67.47 (−11.90%) |
Aug 26, 2026 5w ago | Press Release | $79.37 $66.28 | ▼ −16.49% | ▼ −16.72% | $67.47 (−14.99%) |
Aug 22, 2026 5w ago | Institutional Cluster | $81.07 $69.23 | ▼ −14.60% | ▼ −15.92% | $67.47 (−16.77%) |
Aug 17, 2026 6w ago | 8-K | $79.89 $72.38 | ▼ −9.40% | ▼ −7.87% | $67.47 (−15.54%) |
Aug 13, 2026 7w ago | Press Release | $79.86 $72.38 | ▲ +9.37% | ▲ +7.38% | $67.47 (+15.51%) |
Aug 10, 2026 7w ago | 8-K | $84.67 $76.08 | ▼ −10.15% | ▼ −9.09% | $67.47 (−20.31%) |
Aug 10, 2026 7w ago | Press Release | $84.67 $76.08 | ▼ −10.15% | ▼ −9.09% | $67.47 (−20.31%) |
Jul 13, 2026 11w ago | Insider Cluster | $83.08 $84.67 | ▲ +1.91% | ▼ −1.27% | $67.47 (−18.78%) |
Jun 28, 2026 13w ago | Press Release | $72.01 $84.02 | ▲ +16.68% | ▲ +16.96% | $67.47 (−6.30%) |
Jun 24, 2026 14w ago | 144 | $69.69 $82.93 | ▲ +19.00% | ▲ +18.47% | $67.47 (−3.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access